Considerations to accelerating and maximize the preclinical studies to a safe and effective COVID-19 vaccine
<p>The emergence of novel coronavirus-2019 (COVID-19) by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and its rapid spread across the world have triggered a global health emergency without preceding. From the first report of COVID-19 at Wuhan city of China in December 201...
Saved in:
| 主要作者: | |
|---|---|
| 格式: | 圖書 |
| 出版: |
Journal of Vaccines and Immunology - Peertechz Publications,
2021-01-25.
|
| 主題: | |
| 在線閱讀: | Connect to this object online. |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| 總結: | <p>The emergence of novel coronavirus-2019 (COVID-19) by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and its rapid spread across the world have triggered a global health emergency without preceding. From the first report of COVID-19 at Wuhan city of China in December 2019 until today there has been an outbreak of COVID-19 around the world, with 97, 831, 595 confirmed cases and 2, 120, 877 death cases [1,2] and this number keeps growing.</p><p><br></p> |
|---|---|
| DOI: | 10.17352/jvi.000037 |